QRT-PCR for BCR-ABL, compared to a housekeeping gene (usually ABL), accurately reflects the amount of residual leukemia and, at time points from 3 months of therapy, is used to determine whether patients have an optimal response to TKI. This evidence concerns the gene ABL1 and leukemia.